The relationship between quality of life, cognition, and thyroid status in Graves’ disease
- 106 Downloads
To assess quality of life (QoL) and cognitive function among Graves’ disease (GD) patients with different thyroid status, with and without ophthalmopathy.
This is a cross-sectional clinic-based study involving 154 patients with GD (81.27% were female, mean age 45.6 ± SD 11.2 years) and 54 (35.06%) had ophthalmopathy. Data were collected after an informed consent from all patients was obtained. All patients completed the 36-Item Short Form Health Survey and Mini-Mental State Examination. Patients with ophthalmopathy also completed the Graves’ Orbitopathy Quality of Life Questionnaire.
Patients with hyperthyroidism presented a greater impairment in QoL when compared to euthyroidism group. A lower score in physical role functioning was found in both subgroups with active disease (hyperthyroidism and euthyroidism using thionamides). A lower score was also seen in visual function, only in patients with hyperthyroidism, without difference in appearance. No difference was found in cognition between patients. Younger ages at diagnosis, male sex, euthyroidism and absence of ophthalmopathy were factors associated with better QoL, as well as a shorter disease duration was associated with better recall, attention and calculation.
An impairment in QoL among patients with active GD was evidenced, even in those receiving thionamides and in euthyroidism. Ophthalmopathy was a factor associated with a poor QoL and no clear evidence of cognitive impairment was demonstrated.
KeywordsGraves’ disease Graves’ ophthalmopathy Quality of life Cognitive function Hyperthyroidism
We acknowledge all the patients who voluntarily participated in our study.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 6.M. Abraham-Nordling, O. Torring, B. Hamberger, G. Lundell, L. Tallstedt, J. Calissendorff et al. Graves’ disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 15(11), 1279–1286 (2005). https://doi.org/10.1089/thy.2005.15.1279 CrossRefGoogle Scholar
- 7.P. Cramon, K.H. Winther, T. Watt, S.J. Bonnema, J.B. Bjorner, O. Ekholm et al. Quality-of-life impairments persist 6 months after treatment of Graves’ hyperthyroidism and toxic nodular goiter: a prospective cohort study. Thyroid 26(8), 1010–1018 (2016). https://doi.org/10.1089/thy.2016.0044 CrossRefGoogle Scholar
- 9.M.N. Gerding, C.B. Terwee, F.W. Dekker, L. Koornneef, M.F. Prummel, W.M. Wiersinga, Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7(6), 885–889 (1997). https://doi.org/10.1089/thy.1997.7.885 CrossRefGoogle Scholar
- 12.H.M. Conaglen, J.A.U. Tamatea, J.V. Conaglen, M.S. Elston, Treatment choice, satisfaction and quality of life in patients with Graves’ disease. Clin. Endocrinol. (2018). https://doi.org/10.1111/cen.13611
- 13.J.G. Ljunggren, O. Torring, G. Wallin, A. Taube, L. Tallstedt, B. Hamberger et al.Quality of life aspects and costs in treatment of Graves’ hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 8(8), 653–659 (1998). https://doi.org/10.1089/thy.1998.8.653 CrossRefGoogle Scholar
- 15.M.F. Schreckenberger, U.T. Egle, S. Drecker, H.G. Buchholz, M.M. Weber, P. Bartenstein et al. Positron emission tomography reveals correlations between brain metabolism and mood changes in hyperthyroidism. J. Clin. Endocrinol. Metab. 91(12), 4786–4791 (2006). https://doi.org/10.1210/jc.2006-0573 CrossRefGoogle Scholar
- 17.L.C. Delfino, A. Zunino, V. Sapia, M. Croome, V. Ilera, A.T. Gauna, Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves’ disease. Arch. Endocrinol. Metab. 61(4), 374–381 (2017). https://doi.org/10.1590/2359-3997000000252 CrossRefGoogle Scholar
- 22.M.H. Samuels, R. Kaimal, A. Waring, H.A. Fink, K. Yaffe, A.R. Hoffman et al.Thyroid function variations within the reference range do not affect quality of life, mood, or cognitive function in community-dwelling older men. Thyroid 26(9), 1185–1194 (2016). https://doi.org/10.1089/thy.2016.0104 CrossRefGoogle Scholar
- 23.J.H. Moon, S. Ahn, J. Seo et al. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 99(10), 3782–3789 (2014). https://doi.org/10.1210/jc.2013-4454 CrossRefGoogle Scholar
- 25.G. Ceresini, F. Lauretani, M. Maggio, et al. Subclinical hyperthyroidism is the most prevalent thyroid dysfunction in older Italians and is associated with cognitive impairment. J Am Geriatr Soc (2018). https://doi.org/10.1111/j.1532-5415.2008.02080.
- 26.J.H. Moon, Y.J. Park, T.H. Kim, J.W. Han, S.H. Choi, S. Lim, et al. Lower-but-normal serum TSH level is associated with the development or progression of cognitive impairment in elderly: Korean Longitudinal Study on Health and Aging (KLoSHA). J. Clin. Endocrinol. Metab. 99(2), 424–432 (2014). https://doi.org/10.1210/jc.2013-3385 CrossRefGoogle Scholar
- 27.C.E. Aubert, D.C. Bauer, B.R. da Costa, M. Feller, C. Rieben, E.M. Simonsick et al. The association between subclinical thyroid dysfunction and dementia: the health, aging and body composition (Health ABC) study. Clin. Endocrinol. 87(5), 617–626 (2017). https://doi.org/10.1111/cen.13458 CrossRefGoogle Scholar